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2288Objective: Our aim was to compare systemic chemotherapy (CT) with drainage and with pericardial window in
the treatment of neoplastic pericarditis in patients with various malignancies included in the International
Neoplastic Pericarditis Treatment study.
Methods: Patients treated with systemic CT alone (Group A), CT plus drainage (Group B), or CT plus
pericardial window (Group C) were included. Treatment response was defined as complete response (ie, no
more pericardial effusion or masses), partial response (ie, reduced total score, without requiring further treat-
ments), stable disease (ie, unchanged total score), or progressive disease (ie, increased total score). Patients
with partial or complete response were considered responders.
Results: This preliminary report included 175 patients (56.6% male) with a mean age of 54.21  14.26 years.
Gender distribution, age, and follow-up duration was similar for all groups (P>.05). Prevalent cancer types were
lung cancer (50.9%), breast cancer (14.9%), and lymphoma/leukemia (14.9%). Overall, 22.3%, 42.9%, and
34.9% of patients were in treatment group A, B, and C, respectively. There were 132 responders (75.3%).
The rate of responders significantly differed between groups (P<.001); it was significantly higher in Group
B than in Group A (P< .05) and in Group C than in Group B (P ¼ .006). The significant factors affecting
response were therapy (P¼ .002) and extent of effusion (P¼ .037). Kaplan-Meier analysis showed that patients
in Group C had a significantly better survival rate than patients in the other groups (P ¼ .001).
Conclusions: Systemic CT plus pericardial window is a more effective treatment option compared with
systemic CT alone and systemic CT plus drainage in patients with malignant effusions. (J Thorac Cardiovasc
Surg 2014;148:2288-93)See related commentary on pages 2294-5.Pericardial effusion is a common problem causing
morbidity and mortality in patients with malignancy. The
prevalence of cardiac involvement in malignancies is
between 5% and 20% in autopsy series and clinical
studies.1-4 The most common malignancies with
pericardial effusions are lung carcinoma, lymphoma,
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The Journal of Thoracic and Cardiovascular SurThere are several reasons causing pericardial effusions in
malignancies. About 30% of cases are due to radiation ther-
apy; mediastinal lymph node engorgement; systemic tumor
treatment; and viral, bacterial, and autoimmune causes. In
70% of cases the effusion is due to neoplastic invasion of
the pericardium, and systemic chemotherapy (CT) as the
only treatment, often fails. The presence of a large effusion
may require drainage of the fluid to avoid cardiac tampo-
nade, but the effusion tends to relapse if additional treat-
ments are not given. Drainage may be obtained through
pericardiocentesis performed by inserting a catheter with
the Seldinger technique, or creating a pleuropericardial
window. Pericardial window creation is the most common
surgical treatment used for neoplastic pericardial effusions
in association to systemic CT, but there are a limited num-
ber of studies comparing its efficacy to simple pericardio-
centesis. The international multicenter retrospective study
called International Neoplastic Pericarditis Treatment
(INPUT) study was planned to be conducted to evaluate
the outcome of a large number of patients with neoplastic
pericarditis treated according to the usual care in each insti-
tution (systemic CT, local CT, pericardial drainage, and
pericardial window). In a preliminary report, the efficacy
of 4 treatments alone or in combination (pericardial
drainage, sclerosing therapy, or local or systemic CT) in a
subgroup of lung cancer patients was analyzed.7 In thisgery c November 2014
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INPUT ¼ International Neoplastic Pericarditis
Treatment study
VATS ¼ video-assisted thoracoscopic surgery
C¸elik et al General Thoracic Surgeryreport, only lung cancer patients were included, and none of
the patients had been treated by pericardial window, thus
leaving the open question if pericardial window is more
effective than drainage in preventing recurrences.
The aim our study was to compare the outcome of
neoplastic pericarditis treated either with systemic CTalone
(without drainage), with drainage, and with pericardial win-
dow formation in patients with various malignancies,
among those included in the INPUT study.G
T
SMATERIALS AND METHODS
According to the INPUT study, the neoplastic nature of the effusion has
to be confirmed by cytology, histopathology, or elevated tumor markers in
patients undergoing drainage. Patients with small pericardial effusion did
not undergo pericardial drainage; in those patients, the diagnosis of
neoplastic effusion was confirmed by the presence of intrapericardial
neoplastic masses (detected by computed tomography or positron emission
tomography) or by cytology if the effusion worsened and was finally
drained. Patients who died within 15 days (for causes not related to the peri-
cardial procedures) or could not be followed-up were excluded. The
ongoing INPUT study is currently including 11 centers from 5 countries.
For our study, among the total group of 326 patients we considered the sub-
group comprising 175 patients treated by systemic CT alone, without
drainage (Group A); CT plus drainage (Group B); or CT plus pericardial
window (Group C). We excluded 33 patients who did not receive any CT,
and 118 patients who were treated by local CT alone or in combination
with systemic CT. This subgroup included the patients observed in 8 centers
in 3 countries, namely, Belgium,Turkey, and Italy. All patients received sys-
temic CTaccording to their primary tumor and to the state of art at the time
of their disease. The choice between catheter drainage and pericardial win-
dow depended on the routine approach in different hospitals.
Each patient was treated according to the clinical knowledge at the time
of the treatment, to the attitude of cardiologists, oncologists, and surgeons
of each hospital. Thus, neither ethic committee approval (no changes from
routine local practice), nor informed consent was required (excluding the
usual consent for invasive procedures).
Thenames of patientswere obtained fromhospital records, and follow-up
data were obtained by follow-up appointments and from hospital records.
The follow-up was based on imaging techniques (ie, echocardiography,
computed tomography scan, magnetic resonance imaging, and positron
emission tomography) or autopsy data. Telephone follow-up was used to re-
cord the date of death only. The database includes patients seen at Centro di
Riferimento Oncologica National Cancer Institute, Aviano, Italy, between
1985and2012, andbetween1999 and2012 in theother participating centers.
Pericardiocentesis was performed using the Seldinger technique and in-
serting a pigtail catheter in the pericardial space. After drainage, the cath-
eter was left in place until no significant amount of fluid was drained.
For the creation of a pericardial window, left anterior minithoracotomy
(4-5 cm) techniquewas used under general anesthesia. Patients were placed
in the left lateral decubitis position. Each patient’s chest was opened be-
tween the fourth and fifth intercostal spaces. A 4 3 4 cm or 5 3 5 cm
portion of the left pericardium was excised. Fluid and pericardium sampleThe Journal of Thoracic and Carwas sent for histologic examination. A drainage tube was inserted into the
pleural space and left in place for the following 3 to 4 days.
A scoring system, including both the amount of effusion and the size of
the neoplastic pericardial masses was used to assess the disease at presen-
tation and the outcome of the treatment, as already described.7 Extent of
effusion was graded (effusion score) such that 0 ¼ no effusion, 1 ¼< 1
cm, 2¼ 1 to 2 cm, 3¼ 2 to 3 cm, and 4¼>3 cmmean separation on apical
view (or at CT scan). Mass score was graded such that 1¼ a single
mass<23 2 cm; 2¼multiple masses, or a single mass>23 2 cm or su-
perficial infiltration; and 3 ¼ tumor encasement or transmural infiltration.
The outcomewas considered at the last available follow-up or at the time
when a new treatment (first or new pericardial drainage or pericardial win-
dow after drainage) was chosen because of worsening, relapse, or incom-
plete response. The response was classified as complete response (no
more pericardial effusion or masses; score¼ 0), partial response (reduction
of the total score, without requiring further treatments), stable disease (un-
changed total score), or progressive disease (increased total score).
Patients who had partial or complete response were considered re-
sponders, whereas thosewith stable disease or progression were considered
nonresponders.
Statistical Analysis
Data were analyzed using the Statistical Package for the Social Sciences
version 13 (IBM-SPSS Inc, Armonk, NY). Descriptive statistics were given
as mean  standard deviation, median, or number (percent). The c2 test
was used to compare the rate of responders in the groups and for post
hoc analysis. Forward stepwise logistic regression analysis (Wald method)
was used to determine the variables affecting response. Kaplan-Meier sur-
vival analysis was performed to determine survival in the groups.RESULTS
Our preliminary report included 175 patients (56.6%
male) with a mean age of 54.21  14.26 years (range,
15-84.9 years), from the cardiology, cardiology/oncology,
surgery, and thoracic surgery departments of 8 centers
from3different countries.Most of the patientswere enrolled
from the cardiology/oncology department (34.3%), fol-
lowed by surgery (29.1%), thoracic surgery (20%), and
cardiology (16.6%).
Gender distribution, mean age, and mean follow-up dura-
tion was similar for all groups (P>.05). The types of cancer
were lung cancer in 89 patients (50.9%), breast cancer in 26
patients (14.9%), lymphoma/leukemia in 26 patients
(14.9%), and other types of cancer in 34 patients
(19.3%). Although there was a somewhat even distribution
regarding cancer types in Group A, most of the patients in
Group B and C had lung cancer. The demographic charac-
teristics and outcome of the patients are given in Table 1.
Overall, 22.3% of patients (n ¼ 39) were in Group A,
whereas 42.9% (n ¼ 75) and 34.9% (n ¼ 61) of patients
were in Group B and Group C, respectively.
The effusion was<1 cm in only 16% of patients, and
more than half of patients (50.9%) had a single
mass<2 3 2 cm (mass score ¼ 1). The extent of effusion
(effusion scores) and patients’ mass scores are given in
Table 2. An effusion score  3 was present in 6 patients
in Group A, in 56 patients in Group B, and in 31 patients
in Group C. In Groups B and C, pericardial drainage indiovascular Surgery c Volume 148, Number 5 2289














Female 21 (53.8) 30 (40.0) 25 (41.0) .328 — — —
Male 18 (46.2) 45 (60.0) 36 (59.0)
Age, y 51.09  17.55 55.03  14.08 55.2  11.9 .302 — — —
Follow-up, d 302.08  567.1 301.71  537.45 238.25  287.94 .934 — — —
Site of primary neoplasm
Lung 7 (17.9) 47 (62.7) 35 (57.4) .001 <.001 .001 .748
Breast 10 (25.6) 7 (9.3) 9 (14.8)
Lymphoma/leukemia 11 (28.2) 9 (12) 6 (9.8)
Other 11 (28.2) 12 (16) 11 (18.0)
Response
Yes 21 (53.8) 55 (73.3) 56 (91.8) <.001 .036 <.001 .006
No 18 (46.2) 20 (26.7) 5 (8.2)
Response type
Complete response 10 (25.6) 22 (29.3) 19 (31.1) <.001 .003 <.001 .022
Partial response 11 (28.2) 33 (44.0) 37 (60.7)
Stable disease 4 (10.3) 14 (18.7) 5 (8.2)
Progression 14 (35.9) 6 (8.0) 0 (0.0)
Overall observation time from diagnosis
to last follow-up or to event, d
>30 36 (92.3) 65 (86.7) 52 (85.2) .563 — — —
>60 31 (79.5) 52 (69.3) 47 (77.0) .415 — — —
>180 16 (41.0) 27 (36.0) 25 (41.0) .798 — — —
>365 5 (12.8) 13 (17.3) 13 (21.3) .552 — — —
Data are presented as mean  standard deviation or n (%). *For the post-hoc analysis, P<.017 was considered significant.
General Thoracic Surgery C¸elik et al
G
T
S patients with an effusion score<3 was performed for diag-
nostic purposes or to prevent cardiac tamponade in
loculated effusions.
Overall, 132 patients (75.3%) showed response to ther-
apy; 51 of whom showed complete response, whereas 81
patients showed partial response. The number of patients
who showed response to therapy was 21 (53.8%), 55
(73.3%), and 56 (91.8%) in Groups A, B, and C, respec-
tively (P<.001). A post-hoc analysis showed that the rate
of responders were significantly higher in Group B than
in Group A (P< .05) and in Group C than in Group B
(P ¼ .006) (Table 1).
A logistic regression analysiswas performed to determine
the factors affecting response to therapy. Gender, age, mass,TABLE 2. Effusion and mass scores of the patients










Data are presented as n (%).
2290 The Journal of Thoracic and Cardiovascular Surextent of effusion, and therapy was entered and it was found
that therapy (P ¼ .002) and extent of effusion (P ¼ .037)
were the significant factors affecting response, whereas
gender, age, and mass of the tumor were not significant.
Kaplan-Meier survival analysis showed that patients in
Group C had a significantly better survival rate than the
other groups (P ¼ .001) (Figure 1).
Pericardiocentesis had no major complications. Transi-
tory lowering of blood pressure was successfully cured by
leg elevation or intravenous fluid administration. There
was no procedure-related mortality and major morbidity
in patients undergoing pericardial window formation. Peri-
cardiocentesis was performed in patients with cardiac tam-
ponade to prevent low cardiac output syndrome just before
the operation.DISCUSSION
Pericardial effusion requiring therapy is not an unusual
condition in malignancies. In our study, in which 175 pa-
tients with malignant pericardial effusion were included, a
new scoring system using the extent of effusion (measured
in centimeters), and tumor mass in the equation, defined by
Lestuzzi and colleagues,7 was used to assess treatment
response. Overall, 74.2% of patients showed complete
response to either systemic CT, systemic CT plus drainage,
or systemic CT plus pericardial window formation.gery c November 2014
FIGURE 1. Kaplan-Meier survival curve. In 1 case follow-up was truncated to 3290 days; this is the max value plotted. CT, Chemotherapy; N.S., not
significant.
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SAccording to treatment responses and survival estimations,
the best treatment option in this group of patients seems to
be pericardial window formation plus systemic CT. The
logistic regression analysis showed that extent of effusion
and treatment modality used were the significant factors
affecting treatment response.
Pericardial involvement is usually secondary to a primary
tumor. The most common secondary malignant tumors
involving the pericardium are lung cancer, breast cancer,
malignant melanoma, lymphoma, and leukemia.2,6 As is
reported in the literature, more than half of our patients
(50.9%) were lung cancer patients, followed by breast
cancer and lymphoma/leukemia patients at the same rate
(14.9%).
Various treatment modalities either alone or in combina-
tion have been used in the treatment of malignant pericar-
dial effusion in patients with cancer. However, there is
still no consensus on the best treatment option, given the
wide spectrum of malignancies involving the pericardium,
the different causes of pericardial effusion in malignant pa-
tients, and the clinical condition of individual patients. The
aims of treatment in patients with malignant pericardial ef-
fusions include symptom relief, prevention of recurrences,
treatment of local disease, and improvement of quality of
life. Treatment should prolong survival with minimal
procedure-related morbidity and mortality. Immediate re-
lief of symptoms may be obtained with percutaneous
drainage or with a surgical approach. For long-term preven-
tion of recurrences, various modalities such as extended
drainage, pericardial window (surgical or percutaneousThe Journal of Thoracic and Carballoon pericardiostomy), local sclerosing therapy, local
and/or systemic CT, or radiation therapy, have been used
in the literature.1,8,9
There is no large-scale study comparing outcomes in pa-
tients treated with CT alone. Nevertheless, in a prospective
study on 32 patients with non-Hodgkin’s lymphoma, 5 of 17
cases with pericardial effusion underwent pericardiocente-
sis. The authors stated that the presence of pericardial effu-
sion had no adverse effect on survival at 1 year in advanced
non-Hodgkin’s lymphoma.10 Furthermore, Reynolds and
colleagues11 treated malignant pericardial effusion with a
single pericardiocentesis followed by intensive systemic
combination CT in 3 patients with metastatic carcinoma
of the breast. Available data support the use of systemic
CT in previously untreated patients with highly
CT-sensitive tumors like lymphoma and leukemia.12 Ac-
cording to the response rates obtained in our study, we
also think that systemic CT may be effective in treating
neoplastic pericarditis due to breast cancer and lymphomas,
but has little effect in patients with lung cancer.
Percutaneous pericardiocentesis is usually followed by a
definitive medical or surgical procedure designed to prevent
further fluid accumulation, to provide an alternative
drainage site to prevent cardiac tamponade,13 and to obtain
a diagnosis, but have some risks such as cardiac and coro-
nary laceration, pneumothorax, liver trauma, and death.
Echocardiographic guidance considerably enhances the
safety of this procedure. However, 40% to 90% of pericar-
dial effusions will recur within 3 months after pericardio-
centesis alone, and extended catheter drainage, whichdiovascular Surgery c Volume 148, Number 5 2291
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Clinic cardiologists as their technique of choice.2,9
Studies comparing percutaneous pericardiocentesis with
various treatment modalities like pericardial window for-
mation or surgery have contradictory results. Although
some researchers report beneficial results and no major
procedure-related complications, as do Kabukcu and col-
leagues,14 some report unsuccessful results, requirement
of repeat pericardiocentesis, and complications like right
ventricular puncture.15-17
In patients with symptoms or clinical cardiac tamponade,
pericardiocentesis provides symptom relief, but does not
improve survival and does have a high recurrence rate.
Echocardiographic-guided pericardiocentesis gave a
74.2% complete response rate in our study, without any sig-
nificant procedure-related morbidity with this technique.
The most commonly used surgical approach is pericar-
diotomy or the creation of a pericardial window connected
to a drainage tube or draining into the pleural space (using
the subxiphoid approach, a left thoracotomy, video-assisted
thoracoscopic surgery [VATS], or a balloon catheter).9
The studies using VATS in the treatment of pericardial ef-
fusions reported few or no recurrence in their series.18,19
However, because VATS requires single-lung ventilation
and double-lumen anesthesia, it cannot be performed, espe-
cially in patients with hemodynamic instability.
Subxiphoid approach performed under local anesthesia is
an easier technique, but it is associated with high recurrence
rates.20 Therefore, creating a pericardial window by subxi-
phoid method should not be preferred in patients with a high
probability of long-term survival.
Pericardial window via anterior minithoracotomy is asso-
ciated with lower morbidity, nomortality, and a lower recur-
rence rate, but recovery is delayed.21,22
Cullinane and colleagues23 reviewed 62 patients with
malignant disease who underwent surgical pericardial win-
dow creation for management of pericardial effusions. Win-
dows were created either thoracoscopically (n ¼ 32), by
subxiphoid approach (n ¼ 12), or by limited thoracotomy
approach (n ¼ 18). Primary tumors included non–small
cell lung carcinoma as well as breast, hematologic, and
other solid-organ malignancies. Three patients had recur-
rent effusions (4.8%); 2 in the subxiphoid group and 1 in
the thoracoscopy group. The median survival was shorter
for patients with non–small cell lung carcinoma (2.6
months) than for patients with breast cancer (11 months)
or hematologic malignancy (10 months). The authors
concluded that surgical pericardial window is a safe and
durable operative procedure that may provide extended
survival in certain subgroups of cancer patients.23
In 1 of our previous studies, we also investigated the
effectiveness of pericardial window formation via minithor-
acotomy for treating pericardial tamponade in 48 cancer pa-
tients.22 There was no surgery-related mortality and the2292 The Journal of Thoracic and Cardiovascular Sur30-day mortality rate was 8.33% (all during postoperative
hospitalization). Morbidity rate was 18.75%. Symptomatic
recurrence rate was 2.08%. Cancer type and nature of the
pericardial effusion were the major factors determining
long-term survival (P< .001 and P< .004, respectively).
As mentioned, the major reason for preferring left minithor-
acotomy for creating a pericardial window in our clinic is
that this group of patients needs prompt and definitive diag-
nosis and treatment. This technique has some advantages,
like not requiring single-lung ventilation; it can be per-
formed in only 25 to 30 minutes; and it provides a larger
window, thus allows obtaining a larger tissue sample; and
it offers the opportunity for pleural biopsy. The most impor-
tant disadvantage is the risk of sudden hypotension during
induction of general anesthesia, but this risk can be over-
come by pericardiocentesis performed immediately before
the procedure. For this reason, echo-guided pericardiocent-
esis was performed in all patients before the pericardial
window procedure in our study, and no intraoperative prob-
lems were encountered in these patients.
However, if pericardiocentesis is easy and safe (ie, there is
a safe approach according to echocardiography, with>2 cm
free space between parietal and visceral pericardium,
without interposed organs or masses, either from the subxi-
foid or apical approach), and there are cardiologists able to
do it, percutanous pericardial drainage may be the preferred
approach. In case of difficult/harmful approach (eg, enlarged
liver, moderate effusion with signs of tamponade, and
effusive-constrictive pericarditis) or relapse after pericardio-
centesis and chemotherapy, a surgical approach is suggested.
In a previous work, intrapericardial CTwith platinum de-
rivatives was significantly superior to systemic CT in lung
cancer neoplastic pericarditis,7 and this success was sup-
posed to be due to the local action of platinum within the
lymphatic vessels.7 This approach is possible only using
an intrapericardial catheter. In a more recent report in a
larger group of patients with neoplastic pericarditis,24 the
advantage of intrapericardial CTwas confirmed in lung can-
cer, but not in all kinds of tumors. Our study is the first to
compare pericardial drainage and pericardial window out-
comes. It might be considered the basis for possible further
prospective randomized studies, which would require a
large number of institutions all with cardiac or thoracic sur-
gery facilities; a long enrolment period; and the ethical
problem of proposing a more invasive approach against a
procedure (percutaneous pericardiocentesis) that is usually
well tolerated and excluding the use of intrapericardial
chemotherapy, which has been shown to be useful in a sub-
group of patients with lung cancer.
Study Limitations
Our study was an observational multidisciplinary study on
patients with various malignancies; patient names and char-
acteristics were obtained from hospital records andgery c November 2014
C¸elik et al General Thoracic Surgeryfollow-up data were obtained from follow-up appointments
and fromhospital records. Therefore, there is neither random-
ization nor standardization of the procedures for practical and
ethical reasons; interventions were determined by individual
preferences (patient and physician) and practice patterns.
However, our study design allowed us to make compari-
sons between systemic CT alone, systemic CT plus
drainage, and systemic CT plus pericardial window crea-
tion. A prospective randomized study would be very hard
to perform for practical reasons because hospitals without
cardiac or thoracic surgery facilities should send the pa-
tients elsewhere, which might be impossible in an emer-
gency. Furthermore, in hospitals where the surgical
approach is routinely used, cardiologists may not have
adequate skills to perform a percutaneous pericardiocente-
sis. Furthermore, to increase the validity of our results,
only patients with neoplastic effusion confirmed by
cytology, histopathology, or elevated tumor markers were
included in the study, and we used an objective scoring
system to assess the treatment response.G
T
SCONCLUSIONS
According to the results of our study (including 175 pa-
tients with neoplastic pericarditis), systemic CT plus peri-
cardial window creation is a more effective treatment
option compared to systemic CT alone and systemic CT
plus drainage in patients with malignant effusions.
We believe a significant subgroup of patients may
improve with treatment including pericardial drainage
plus local and/or systemic CT, mostly patients with lung
cancer or with highly chemosensitive tumors. Pericardial
window creation (even with the mini-invasive method of
balloon pericardiostomy) is an effective and safe second
line treatment in relapsing effusion after pericardial
drainage, and in cases refractory to other therapeutic ap-
proaches. It can be used as first-line treatment in patients
with malignant neoplasms less likely to be successfully
treated by local or systemic CT, such as mesotheliomas
and sarcomas, or whenever the possibility of an intraperi-
cardial therapy is excluded by an oncologist.References
1. Buzaid AC, Garewal HS, Greenberg BR. Managing malignant pericardial effu-
sion. West J Med. 1989;150:174-9.
2. Grannis FW Jr, Lai L, Kim JY. Fluid complications. http://www.cancernetwork.
com/cancer-management/fluid-complications/article/10165/1802878. Accessed
April 21, 2014.
3. MaischB, Ristic A, Pankuweit S. Evaluation andmanagement of pericardial effu-
sion in patients with neoplastic disease. Prog Cardiovasc Dis. 2010;53:157-63.The Journal of Thoracic and Car4. MacGee W. Metastatic and invasive tumours involving the heart in a geriatric
population: a necropsy study. Virchows Arch A Pathol Anat Histopathol. 1991;
419:183-9.
5. Abraham KP, Reddy V, Gattuso P. Neoplasms metastatic to the heart: review of
3314 consecutive autopsies. Am J Cardiovasc Pathol. 1990;3:195-8.
6. Lam KY, Dickens P, Chan AC. Tumors of the heart. A 20-year experience with a
review of 12,485 consecutive autopsies. Arch Pathol Lab Med. 1993;117:
1027-31.
7. Lestuzzi C, Bearz A, Lafaras C, Gralec R, Cervesato E, Tomkowski W,
et al. Neoplastic pericardial disease in lung cancer: impact on outcomes
of different treatment strategies. A multicenter study. Lung Cancer. 2011;
72:340-7.
8. Tsang TS, Seward JB, Barnes ME, Bailey KR, Sinak LJ, Urban LH, et al. Out-
comes of primary and secondary treatment of pericardial effusion in patients with
malignancy. Mayo Clin Proc. 2000;75:248-53.
9. Lestuzzi C. Neoplastic pericardial disease: old and current strategies for diag-
nosis and management. World J Cardiol. 2010;2:270-9.
10. Acquatella GC, Roura ET, Maury AJ, Stern RO, Acquatella H. High incidence of
pericardial effusion in non-Hodgkin’s lymphoma: usefulness of echocardiogra-
phy. Eur J Cancer Clin Oncol. 1982;18:1131-6.
11. Reynolds PM, Byrne MJ. The treatment of malignant pericardial effusion in car-
cinoma of the breast. Aust N Z J Med. 1977;7:169-71.
12. Lamont E, Hoffman PC. Oncologic emergencies. In: Hall JB, Schmidt GA,
Wood LDH, eds. Principles of critical care. 3rd ed. New York: McGraw Hill;
2005.
13. Maher EA, Shepherd FA, Todd TJ. Pericardial sclerosis as the primary manage-
ment of malignant pericardial effusion and cardiac tamponade. J Thorac Cardi-
ovasc Surg. 1996;112:637-43.
14. Kabukcu M, Demircioglu F, Yanik E, Basarici I, Ersel F. Pericardial tamponade
and large pericardial effusions: causal factors and efficacy of percutaneous cath-
eter drainage in 50 patients. Tex Heart Inst J. 2004;31:398-403.
15. Little AG, Kremser PC, Wade JL, Levett JM, DeMeester TR, Skinner DB. Oper-
ation for diagnosis and treatment of pericardial effusions. Surgery. 1984;96:
738-44.
16. Laham RJ, Cohen DJ, Kuntz RE, Baim DS, Lorell BH, Simons M. Pericardial
effusion in patients with cancer: outcome with contemporary management stra-
tegies. Heart. 1996;75:67-71.
17. Gumrukcuoglu HA, Odabasi D, Akdag S, Ekim H. Management of car-
diac tamponade: a comparative study between echo-guided pericardiocent-
esis and surgery-a report of 100 patients. Cardiol Res Pract. 2011;2011:
197838.
18. O’Brien PK, Kucharczuk JC, Marshall MB, Friedberg JS, Chen Z, Kaiser LR,
et al. Comparative study of subxiphoid versus video-thoracoscopic pericardial
‘‘window’’ Ann Thorac Surg. 2005;80:2013-9.
19. Uramoto H, Hanagiri T. Video-assisted thoracoscopic pericardiectomy for malig-
nant pericardial effusion. Anticancer Res. 2010;30:4691-4.
20. Mueller XM, Tevaearai HT, Hurni M, Ruchat P, Fischer AP, Stumpe F, et al.
Long-term results of surgical subxiphoid pericardial drainage. Thorac Cardio-
vasc Surg. 1997;45:65-9.
21. Neragi-Miandoab S, Linden PA, Ducko CT, Bueno R, Richards WG,
Sugarbaker DJ, et al. VATS pericardiotomy for patients with known malignancy
and pericardial effusion: survival and prognosis of positive cytology and meta-
static involvement of the pericardium: a case control study. Int J Surg. 2008;6:
110-4.
22. Celik S, Celik M, Aydemir B, Tanrikulu H, Okay T, Tanrikulu N. Surgical prop-
erties and survival of a pericardial window via left mini thoracotomy for benign
and malignant pericardial tamponade in cancer patients. World J Surg Oncol.
2012;10:123.
23. Cullinane CA, Paz IB, Smith D, Carter N, Grannis FW Jr. Prognostic factors in
the surgical management of pericardial effusion in the patient with concurrent
malignancy. Chest. 2004;125:1328-34.
24. Lestuzzi C, Cervesato E, Lafaras C, Celik S, Dequanter D, Tomkowski W, et al.
Which is the best approach for neoplastic pericardial effusion? A retrospective
analysis of 264 cases. Eur Heart J. 2013;34(Suppl 1):P4483.diovascular Surgery c Volume 148, Number 5 2293
